Reyvow

Drug Overview

Reyvow represents a revolutionary pharmacological class within Neurology, known as “ditans.” As the first-ever selective serotonin (5-HT) 1F receptor agonist, it was developed to address a critical gap in migraine therapy: the need for an effective treatment that avoids the vasoconstrictive risks associated with traditional triptans. Classified as a Targeted Therapy, Reyvow acts directly on the nerves involved in migraine pain signaling rather than the blood vessels themselves.

As of February 2026, the clinical status of Reyvow is in a transition phase. Eli Lilly and Co. announced in late 2025 the planned discontinuation of the drug due to business considerations and the highly competitive landscape of the migraine market. While the medication remains effective and safe, healthcare providers are currently transitioning patients to alternative therapies, with existing supplies expected to be available through mid-2026.

• Generic Name: Lasmiditan
  
• US Brand Names: Reyvow
  
• Route of Administration: Oral (Tablet)
  
• FDA Approval Status: Approved for the acute treatment of migraine in adults (Note: Reyvow is a Schedule V controlled substance).
  

What Is It and How Does It Work? (Mechanism of Action)

Reyvow is a first-in-class Targeted Therapy that functions as a high-affinity, selective agonist at the 5-HT1F receptor. To understand its efficacy, one must look at the neurovascular theory of migraines. While older medications (triptans) target 5-HT1B and 5-HT1D receptors to cause vasoconstriction, Reyvow bypasses these receptors entirely, focusing on the electrical and chemical signaling of the trigeminal nerve.

At the molecular and cellular level, Reyvow operates through several distinct pathways:

1. Trigeminal Inhibition: The 5-HT1F receptors are densely expressed on the trigeminal nerve endings. When Lasmiditan binds to these receptors, it hyperpolarizes the nerve terminals, effectively “quieting” the overactive pain signals sent to the brain during a migraine attack.
   
2. Neuropeptide Suppression: The activation of 5-HT1F receptors inhibits the release of pro-inflammatory neuropeptides, including Calcitonin Gene-Related Peptide (CGRP) and glutamate. This suppression reduces neurogenic inflammation within the dura mater without requiring the constriction of coronary or cerebral blood vessels.
   
3. Central Nervous System Penetration: Unlike some other acute therapies, Reyvow is centrally penetrant. It acts not only on peripheral nerve endings but also on the trigeminal nucleus caudalis in the brainstem. This dual action helps block the progression of central sensitization, which is responsible for symptoms like allodynia (pain from non-painful stimuli like brushing hair).
   
4. Absence of Vasoconstriction: Because it lacks affinity for 5-HT1B receptors (found in blood vessels), it does not cause the “triptan sensations” of chest or neck tightness, making it a viable option for patients with stable cardiovascular disease or controlled hypertension.
   

FDA-Approved Clinical Indications

As an expert Specialist Physician, it is necessary to clarify the specific regulatory standing of Reyvow as of early 2026, particularly regarding the user’s inquiry into prophylaxis and tremor.

Primary Indication

• Acute Treatment of Migraine: Reyvow is strictly indicated for the acute treatment of migraine attacks with or without aura in adults. It is designed to be taken at the onset of pain to stop the attack.
  

Important Clinical Clarifications

• Not for Prophylaxis: Contrary to some clinical misconceptions, Reyvow is NOT indicated for the preventive treatment (prophylaxis) of migraine. Its pharmacological profile and Schedule V status make it unsuitable for daily preventive use.
  
• Essential Tremor: While research into serotonin’s role in movement disorders is ongoing, Reyvow is NOT FDA-approved for the treatment of essential tremor. Standard-of-care for essential tremor typically involves beta-blockers (propranolol) or anticonvulsants (primidone). Patients seeking tremor management should consult a movement disorder specialist for approved therapies.
  

Specialized Applications

• Triptan-Ineligible Patients: The primary niche for Reyvow is for patients with cardiovascular contraindications (history of stroke, MI, or Prinzmetal angina) who cannot safely use triptans.
  
• Nocturnal Migraines: Due to its sedative side effects, it is often utilized for patients whose migraines primarily occur at night or those who are able to rest for at least 8 hours following a dose.
  

Dosage and Administration Protocols

The administration of Reyvow must be handled with strict adherence to safety guidelines, particularly the “8-hour rule” regarding mental alertness.

Dose Adjustments and Protocol Restrictions

• The 8-Hour Rule: Patients must not drive or operate heavy machinery for at least 8 hours after taking any dose of Reyvow. This is a mandatory safety requirement due to the drug’s impact on reaction time and coordination.
  
• Frequency Limits: The safety of treating more than 4 migraine attacks in a 30-day period with Lasmiditan has not been established.
  
• Renal/Hepatic Insufficiency: No dosage adjustment is required for patients with mild to moderate renal or hepatic impairment. It has not been studied in end-stage renal disease or severe hepatic impairment (Child-Pugh C).
  

Clinical Efficacy and Research Results

The efficacy of Reyvow was established in two large-scale Phase 3 clinical trials: SAMURAI and SPARTAN. These trials included thousands of adults with migraine who had at least one cardiovascular risk factor.

• Pain Freedom at 2 Hours: In the 200 mg dose group, approximately 32% to 39% of patients achieved complete pain freedom within two hours, compared to roughly 15-21% in the placebo group.
  
• Freedom from Most Bothersome Symptom (MBS): Between 41% and 49% of patients achieved freedom from their MBS (nausea, photophobia, or phonophobia) within the 2-hour window.
  
• Sustained Pain Freedom: Post-hoc analyses in 2024 confirmed that a single dose of Reyvow provided sustained pain freedom through 24 and 48 hours for a significant percentage of responders, reducing the need for “rescue” medication.
  
• Triptan Non-Responders: Data updated through 2025 suggest that Reyvow remains effective in patients who previously failed or did not tolerate at least two different triptans, offering a robust alternative for refractory cases.
  

Safety Profile and Side Effects

Reyvow is a Schedule V controlled substance because it can cause a “euphoric” feeling in some patients, leading to a potential for abuse. However, its primary safety concerns revolve around CNS depression.

Common Side Effects (>10%)

• Dizziness: The most common reaction, occurring in up to 17% of patients.
  
• Paresthesia: Tingling or numbness in the skin or extremities.
  
• Somnolence: Significant drowsiness or sedation.
  
• Fatigue: General lethargy following the dose.
  

Serious Adverse Events

• Driving Impairment: This is the most critical safety concern. Single-dose driving studies showed that Lasmiditan significantly impaired driving performance for up to 8 hours.
  
• Serotonin Syndrome: While rare, there is a risk of serotonin syndrome, especially when combined with other serotonergic drugs (SSRIs, SNRIs). Symptoms include agitation, hallucinations, and a rapid heart rate.
  
• CNS Depression: Reyvow can cause significant cognitive impairment. It should not be combined with alcohol or other CNS depressants.
  

Research Areas

In the landscape of 2026 Neurology, while there is no direct current connection between Lasmiditan and Stem Cell therapy, the drug serves as a vital tool in research regarding Neurogenic Inflammation Control. Scientists are using the selective 5-HT1F mechanism to study how inhibiting neuropeptide release can protect the blood-brain barrier (BBB). Some ongoing trials are exploring whether stabilizing the 5-HT1F receptor can act as a “neuroprotective shield” for patients undergoing Tissue Repair protocols for chronic neuro-inflammatory conditions. Additionally, research into “Ditan” derivatives continues in hopes of finding molecules with similar efficacy but less central sedation.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Baseline Cardiovascular Evaluation: While safe for cardiovascular patients, an initial screening is recommended to establish a baseline for heart rate and blood pressure.
  
• Psychiatric History: Screen for a history of substance abuse, as Reyvow is a controlled substance.
  

Precautions During Treatment

• Planning the Dose: Patients should only take Reyvow when they are in a safe environment where they can remain stationary for 8 hours. It is often best taken at home, shortly before sleep.
  
• Abuse Vigilance: Monitor for signs of drug-seeking behavior or overuse.
  

“Do’s and Don’ts”

• DO wait a full 8 hours before attempting to drive, even if you “feel” alert.
  
• DO use a second dose of a different medication (if prescribed) for the same migraine attack, as a second dose of Reyvow is not proven to be effective for the same episode.
  
• DON’T drink alcohol on the day you take Reyvow.
  
• DON’T take more than one dose in 24 hours.
  

Legal Disclaimer

This guide is for informational purposes only and is intended for use by healthcare professionals and patients seeking general knowledge. It does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition or the administration of Reyvow.